Post by Confo Therapeutics

We’re thrilled to announce the nomination of CFTX-2034, our groundbreaking antibody-based SSTR5 agonist, as a development candidate for PBH (Post-Bariatric surgery Hypoglycemia) and other hyperinsulinemia conditions. This significant milestone represents Confo Therapeutics’ first agonistic antibody that has entered IND-enabling studies and underscores the exceptional strength of our GPCR platform as we continue to advance innovative therapies for metabolic and endocrine diseases. Read full article here: https://lnkd.in/er_346yh #GPCR #agonist #antibody #PBH #hyperinsulinemia